secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001104659-23-057445
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q1 revenue $1.257B, adj EPS $0.45; raises low end of FY guidance
-----------------------------------------------------------------------

- Q1 revenue $1,257M (+3% reported, +6% CC); includes estimated $90-110M benefit from ERP blackout.
- Adjusted EPS $0.45 (+25% YoY); reported EPS $0.21 vs $0.10 prior year.
- Full year 2023 guidance raised: revenue $4,310-4,400M, adj EPS $0.76-0.83.
- Q2 guidance expects revenue $1,003-1,053M due to ERP blackout pull-forward; adj EPS $0.00-0.05.
- Net leverage 5.4x; received USDA conditional approval for parvovirus antibody, submitted for IL-31 mAb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465923057445/0001104659-23-057445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465923057445/tm2315016d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer